PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

New England Journal of Medicine 2026

View at publisher
Authors: Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad, F Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, E. Voog, Neal D. Shore, Timuçin Çil, Christof Vulsteke, Hsiao-Jen Chung
+7 more Stefanie Zschäbitz, A. Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi
DOI: 10.1056/nejmoa2604126
Cited by: 9
References: 18

Abstract

BACKGROUND: A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival and overall survival, with the greatest benefit observed in the cohort with alterations in homologous recombination repair genes. METHODS: ) mutation status. The primary end point was investigator-assessed imaging-based progression-free survival. The key secondary end point was overall survival. RESULTS: A total of 300 patients were assigned to the talazoparib group and 299 to the control group. At 3 years, progression-free survival was 77% in the talazoparib group and 56% in the control group (hazard ratio for disease progression or death, 0.48; 95% confidence interval [CI], 0.36 to 0.65; P

Fields of Study & Subjects

PARP inhibition in cancer therapy Prostate Cancer Treatment and Research Estrogen and related hormone effects

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
395
Issue
5
Pages
427–439
Publication date
30 May 2026
Language
EN